novavax featured image
News Pharmaceutical & Biotech Stories

Novavax Starts Late-Stage Trial of COVID-19 Vaccine

Novavax Inc. started a late-stage trial of its experimental coronavirus vaccine in the United Kingdom.

The trial is expected to enroll and test the vaccine in up to 10,000 participants aged between 18 and 84 years over the next four to six weeks.

The study has two main goals, the first occurrence of PCR-confirmed symptomatic COVID-19 at least 7 days after the second study vaccination in volunteers who have not been previously infected with SARS-CoV-2.

The second main goal is the first occurrence of PCR-confirmed symptomatic moderate or severe COVID-19 at least 7 days after the second study vaccination in volunteers who have not been previously infected with the virus.

If the vaccine proves safe, Novavax said it currently has the ability to manufacture 2 billion doses by mid-2021.

Other vaccines backed by Operation Warp Speed are in late-stage testing from Johnson & Johnson, Moderna, Pfizer, and AstraZeneca.

ASEAN HR TECH VENTURE SUMMIT 2018
REGISTER NOW 33% DISCOUNT
SUMMIT PASS

Send this to a friend